Decreased serum carnitine is independently correlated with increased tissue accumulation levels of advanced glycation end products in haemodialysis patients

Nephrology

Volumn 17, Issue 8, 2012, Pages 689-694

  Adachi, Takeki ^a   Fukami, Kei ^a   Yamagishi, Sho Ichi ^b   Kaida, Yusuke ^a   Ando, Ryotaro ^a   Sakai, Kazuko ^a   Adachi, Hisashi ^a   Otsuka, Aki ^c   Ueda, Seiji ^a   Sugi, Kenzo ^c   Okuda, Seiya ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Department of Pathophysiology and Therapeutics of Diabetic Complications ^*  (Japan)

^c Sugi Cardiovascular Hospital   (Japan)

Author keywords

carnitine; glycation; haemodialysis; tissue

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BETA 2 MICROGLOBULIN; CARNITINE;

ADULT; AGED; ARTICLE; AUTOFLUORESCENCE; CARNITINE DEFICIENCY; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEMODIALYSIS PATIENT; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; CARNITINE; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DOWN-REGULATION; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; OPTICAL IMAGING; RENAL DIALYSIS; SKIN; UP-REGULATION;

EID: 84868108631     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2012.01642.x     Document Type: Article

References (25)

1. Brownlee M, Cerami A, Vlassara H,. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 1988; 318: 1315-21.
2. Grandhee SK, Monnier VM,. Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J. Biol. Chem. 1991; 266: 11649-53. (Pubitemid 21906998)
3. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW,. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J. Biol. Chem. 1991; 266: 11654-60. (Pubitemid 21906999)
4. Makita Z, Radoff S, Rayfield EJ, et al,. Advanced glycosylation end products in patients with diabetic nephropathy. N. Engl. J. Med. 1991; 325: 836-42.
5. Vlassara H,. Recent progress in advanced glycation end products and diabetic complications. Diabetes 1997; 46 (Suppl 2): S19-25. (Pubitemid 27377393)
6. Nakamura T, Sato E, Fujiwara N, et al,. Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients. Metabolism 2009; 58: 1624-8.
7. Yamagishi S,. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications. Ther. Apher. Dial. 2009; 13: 534-9.
8. Kilhovd BK, Juutilainen A, Lehto S, et al,. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: A population-based 18-year follow-up study. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 815-20. (Pubitemid 40463875)
9. Kilhovd BK, Juutilainen A, Lehto S, et al,. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: A population-based 18 year follow-up study. Diabetologia 2007; 50: 1409-17. (Pubitemid 46879016)
10. Furuya R, Kumagai H, Miyata T, et al,. High plasma pentosidine level is accompanied with cardiovascular events in hemodialysis patients. Clin. Exp. Nephrol. 2012; 16: 421-6.
11. Meerwaldt R, Hartog JW, Graaff R, et al,. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J. Am. Soc. Nephrol. 2005; 16: 3687-93. (Pubitemid 46211290)
12. Nagano M, Fukami K, Yamagishi S, et al,. Tissue level of advanced glycation end products is an independent determinant of high-sensitivity C-reactive protein levels in haemodialysis patients. Nephrology (Carlton) 2011; 16: 299-303.
13. Lutgers HL, Graaff R, Links TP, et al,. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 2006; 29: 2654-9. (Pubitemid 44912194)
14. Evans AM, Fornasini G,. Pharmacokinetics of L-carnitine. Clin. Pharmacokinet. 2003; 42: 941-67. (Pubitemid 37056103)
15. Evans A,. Dialysis-related carnitine disorder and levocarnitine pharmacology. Am. J. Kidney Dis. 2003; 41: S13-26. (Pubitemid 36389776)
16. Sakurabayashi T, Miyazaki S, Yuasa Y, et al,. L-carnitine supplementation decreases the left ventricular mass in patients undergoing hemodialysis. Circ. J. 2008; 72: 926-31. (Pubitemid 351879913)
17. Ahmad S, Robertson HT, Golper TA, et al,. Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects. Kidney Int. 1990; 38: 912-18. (Pubitemid 20362862)
18. Rajasekar P, Anuradha CV,. L-Carnitine inhibits protein glycation in vitro and in vivo: Evidence for a role in diabetic management. Acta Diabetol. 2007; 44: 83-90. (Pubitemid 46835450)
19. Takahashi M, Ueda S, Misaki H, et al,. Carnitine determination by an enzymatic cycling method with carnitine dehydrogenase. Clin. Chem. 1994; 40: 817-21. (Pubitemid 24142862)
20. Daugirdas JT,. Linear estimates of variable-volume, single-pool Kt/V: An analysis of error. Am. J. Kidney Dis. 1993; 22: 267-70. (Pubitemid 23236633)
21. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S,. Beneficial effects of metformin and irbesartan on advanced glycation end products (AGEs)-RAGE-induced proximal tubular cell injury. Pharmacol. Res. 2012; 65: 297-302.
22. Hou FF, Chertow GM, Kay J, et al,. Interaction between beta 2-microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis. Kidney Int. 1997; 51: 1514-19. (Pubitemid 27239906)
23. Miyata T, Oda O, Inagi R, et al,. Beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J. Clin. Invest. 1993; 92: 1243-52. (Pubitemid 23273898)
24. Inaba M, Kurajoh M, Okuno S, et al,. Poor muscle quality rather than reduced lean body mass is responsible for the lower serum creatinine level in hemodialysis patients with diabetes mellitus. Clin. Nephrol. 2010; 74: 266-72.
25. Savica V, Santoro D, Mazzaglia G, et al,. L-carnitine infusions may suppress serum C-reactive protein and improve nutritional status in maintenance hemodialysis patients. J. Ren. Nutr. 2005; 15: 225-30.